Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 3/20 | 0.38 |
| ▸ | RET | P07949 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 6/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077692 | 0.83 | RET (0.40) | ACVRL1RETKDRENPP1ADORA2A | |
| SCHEMBL410217 | 0.80 | RET (0.40) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL10260070 | 0.67 | RET (0.40) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL19476929 | 0.66 | RET (0.39) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL13968294 | 0.64 | ALDH1A1 (0.31) | RETKDR | |
| SCHEMBL15932550 | 0.64 | RET (0.38) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL14488780 | 0.64 | ACVRL1 (0.52) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL26690322 | 0.64 | ACVRL1 (0.52) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL15932552 | 0.64 | ACVRL1 (0.52) | ACVRL1RETKDRADORA2AADORA1 | |
| SCHEMBL26271741 | 0.62 | ACVRL1 (0.51) | ACVRL1RETKDRADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | PHARMACYCLICS, INC. | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246169-A1 | Inhibitors of Bruton's Tyrosine Kinase for the Treatment of Solid Tumors | BTK, ABL1, LYN | ACVRL1 4164/4885RET 166/4885KDR 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.